アブストラクト
| Title | 6. 消化管 (器) の腫瘍 (5) 特殊型肝臓・胆道・膵臓癌 |
|---|---|
| Subtitle | 希少がん - がん診療の新たな課題 - II. 希少がん疾患各論 |
| Authors | 森實千種 |
| Authors (kana) | |
| Organization | 国立がん研究センター 希少がんセンター, 国立がん研究センター中央病院 肝胆膵内科 |
| Journal | 日本臨牀 |
| Volume | 79 |
| Number | 増刊号1 |
| Page | 332-336 |
| Year/Month | 2021 / |
| Article | 報告 |
| Publisher | 日本臨牀社 |
| Abstract | 「はじめに」肝胆膵領域は治療抵抗性で進行が速い難治癌が多い. 一般的な組織型は肝臓が肝細胞癌, 胆道と膵臓は腺癌である. 本稿ではそれ以外の組織型を「特殊型」とし, 比較的診療の現場で遭遇することが多いもの, 特徴的なものについて抜粋して述べる. 類上皮血管内皮腫などの肉腫や, 小児に多い肝芽腫, 神経内分泌腫瘍については他稿に譲る. 「1. 特殊型肝臓癌」第21回全国原発性肝癌追跡調査報告(2010〜2011年)によると22,134人の原発性肝癌のうち, 肝細胞癌91.4%, 肝内胆管癌6.0%, 細胆管細胞癌0.3%, 胆管嚢胞腺癌0.1%, 混合型肝癌1.0%, 肝芽腫0.03%, 未分化癌0.1%である. 肝細胞癌の特殊型として, fibrolamellar carcinomaがある. 日本の原発性肝癌取扱い規約第6版補訂版では肝細胞癌以外には肝内胆管癌, 細胆管細胞癌(細胆管癌), 粘液嚢胞腺癌, 混合型肝癌, 肝芽腫, その他の分類がある. |
| Practice | 医学総合 |
| Keywords | rare cancer, 肝癌, 胆道癌, 膵癌 |
- 全文ダウンロード： 従量制、基本料金制の方共に1,243円(税込) です。
参考文献
- 1) Quigley B, et al: Hepatobiliary Mucinous Cystic Neoplasms With Ovarian Type Stroma(So-Called "Hepatobiliary Cystadenoma/Cystadenocarcinoma"): Clinicopathologic Analysis of 36 Cases Illustrates Rarity of Carcinomatous Change. Am J Surg Pathol 42: 95-102, 2018.
- 2) Trikalinos NA, et al: Systemic Therapy for Combined Hepatocellular-Cholangiocarcinoma: A Single-Institution Experience. J Natl Compr Canc Netw 16: 1193-1199, 2018.
- 3) Kobayashi S, et al: Multicenter retrospective analysis of systemic chemotherapy for unresectable combined hepatocellular and cholangiocarcinoma. Cancer Sci 109: 2549-2557, 2018.
- 4) Xue R, et al: Genomic and Transcriptomic Profiling of Combined Hepatocellular and Intrahepatic Cholangiocarcinoma Reveals Distinct Molecular Subtypes. Cancer Cell 35: 932-947.e8, 2019.
- 5) Tuncel D, et al: Poorly cohesive cell(diffuse-infiltrative/signet ring cell)carcinomas of the gallbladder: clinicopathological analysis of 24 cases identified in 628 gallbladder carcinomas. Hum Pathol 60: 24-31, 2017.
残りの10件を表示する
- 6) Murimwa G, et al: Comparative Outcomes of Adenosquamous Carcinoma of the Gallbladder: an Analysis of the National Cancer Database. J Gastrointest Surg, 2020.(DOI: 10.1007/s11605-020-04729-w)
- 7) Wang JC, et al: Choriocarcinoma of the gallbladder: treated with cisplatin-based chemotherapy. Med Oncol 18: 165-169, 2001.
- 8) Okabayashi T, et al: Surgical outcomes for 131 cases of carcinosarcoma of the hepatobiliary tract. J Gastroenterol 49: 982-991, 2014.
- 9) Tanaka M, et al: Revisions of international consensus Fukuoka guidelines for the management of IPMN of the pancreas. Pancreatology 17: 738-753, 2017.
- 10) Imaoka H, et al: Clinical characteristics of adenosquamous carcinoma of the pancreas: a matched case-control study. Pancreas 43: 287-290, 2014.
- 11) Fang Y, et al: Chemoradiotherapy is associated with improved survival for resected pancreatic adenosquamous carcinoma: a retrospective cohort study from the SEER database. Ann Transl Med 7: 522, 2019.
- 12) Marcus R, et al: Recent advances in genomic profiling of adenosquamous carcinoma of the pancreas. J Pathol 243: 271-272, 2017.
- 13) Adsay NV, et al: Colloid(mucinous noncystic) carcinoma of the pancreas. Am J Surg Pathol 25: 26-42, 2001.
- 14) Imaoka H, et al: Clinical outcomes of chemotherapy in patients with undifferentiated carcinoma of the pancreas: a retrospective multicenter cohort study. BMC Cancer 20: 946, 2020.
- 15) Holen KD, et al: Clinical characteristics and outcomes from an institutional series of acinar cell carcinoma of the pancreas and related tumors. J Clin Oncol 20: 4673-4678, 2002.
